Plasma Human Cartilage Glycoprotein‐39 and Cognitive Impairment After Acute Ischemic Stroke
Our study aimed at evaluating the association between plasma human cartilage glycoprotein-39 (YKL-40) and cognitive impairment at 3 months among patients with acute ischemic stroke. Plasma YKL-40 levels were measured in 604 participants from the China Antihypertensive Trial in Acute Ischemic Stroke....
Saved in:
Published in | Journal of the American Heart Association Vol. 14; no. 2; p. e036790 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley and Sons Inc
21.01.2025
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Our study aimed at evaluating the association between plasma human cartilage glycoprotein-39 (YKL-40) and cognitive impairment at 3 months among patients with acute ischemic stroke.
Plasma YKL-40 levels were measured in 604 participants from the China Antihypertensive Trial in Acute Ischemic Stroke. Cognitive impairment outcomes were assessed at 3 months poststroke using the Mini-Mental State Examination and the Montreal Cognitive Assessment. According to the Mini-Mental State Examination score, patients in the highest quartile of YKL-40 had a 2.01-fold (95% CI, 1.23-3.29;
for trend=0.009) risk of poststroke cognitive impairment compared with those in the lowest quartile. Each 1 SD difference of logarithm-transformed YKL-40 was associated with a 28% (95% CI, 7-53) increased risk for the outcome. The multiple-adjusted spline regression model confirmed dose-response relationships between YKL-40 and poststroke cognitive impairment (
for linearity=0.01). Adding YKL-40 to a model containing conventional risk factors significantly improved the discriminatory power (area under the receiver operating characteristic curve improved by 0.02,
=0.03). When cognitive impairment was defined using the Montreal Cognitive Assessment score, similar findings were observed.
Elevated YKL-40 levels were associated with an increased risk of cognitive impairment at 3 months among patients with acute ischemic stroke.
URL: clinicaltrials.gov; Unique Identifier: NCT01840072. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 This manuscript was sent to Michelle H. Leppert, MD, MBA, Associate Editor, for review by expert referees, editorial decision, and final disposition. For Sources of Funding and Disclosures, see page 8. |
ISSN: | 2047-9980 2047-9980 |
DOI: | 10.1161/JAHA.124.036790 |